Umoja Biopharma

Seattle, WA · Founded 2019 · Privately Held (backing)

Operator of a biotechnology platform designed to advance a novel approach to cancer immunotherapy by generating engineered immune cells. Umoja Biopharma is based in Seattle, WA and was founded in 2019. It is valued at about $509 million as of Oct 2026, set by institutional fund marks, up 21% since its later-stage round in Jan 2025. It has raised $371 million across 1 recorded round; the latest was a $210 million later-stage round in Jun 2021.

PMV mark · valuation
$508.8M
Oct 2026
Since last round
+21%
Jan 2025
Total raised
$371.0M
Last round
Later Stage VC
Jun 2021

Who backs Umoja Biopharma?

25 investors
InvestorType
SoftBank Investment AdvisersGrowth equity
Qiming Venture Partners USAVenture capital
Temasek HoldingsOther
Realm Capital VenturesVenture capital
Alexandria Venture InvestmentsOther
Emerson CollectiveOther
ARK Ventures (US)Venture capital
Cormorant Asset ManagementVenture capital
Casdin CapitalVenture capital
RTW InvestmentsHedge fund
+ 15 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Umoja Biopharma investors

25 investors are on record for Umoja Biopharma, including SoftBank Investment Advisers, Qiming Venture Partners USA, Temasek Holdings and Realm Capital Ventures. By type, the record holds 7 venture capital firms and 3 hedge funds. The later-stage round in Jun 2021 drew 29 investors.

Free account
More of Umoja Biopharma with a free account
  • ·The complete investor list: 25 names
  • ·Watch Umoja Biopharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 25 firms already write checks for companies like Umoja Biopharma. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View